Cancers, Vol. 12, Pages 3339: Modulation of de Novo Lipogenesis Improves Response to Enzalutamide Treatment in Prostate Cancer

Alexandros G.Sfakianakis shared this article with you from Inoreader Cancers, Vol. 12, Pages 3339: Modulation of de Novo Lipogenesis Improves Response to Enzalutamide Treatment in Prostate Cancer Μέσω Cancers Cancers, Vol. 12, Pages 3339: Modulation of de Novo Lipogenesis Improves Response to Enzalutamide Treatment in Prostate Cancer Cancers doi: 10.3390/cancers12113339 Authors: Lounis Péant Leclerc-Desaulniers Ganguli Daneault Ruiz Zoubeidi Mes-Masson Saad De novo lipogenesis (DNL) is now considered as a hallmark of cancer. The overexpression of key enzymes of DNL is characteristic of both primary and advanced disease and may play an important role in resistance to therapies. Here, we showed that DNL is highly enhanced in castrate resistant prostate cancer (CRPC) cells compared to hormone sensitive and enzalutamide resistant cells. This observation suggests that this pathway plays an important role in the initiation of aggressive prostate cancer and in the development of enzalutamide resistance. Importantly, here we show that both prostate cancer cells sensitive and resistant to enzalutamide are dependent on DNL to proliferate. We next combined enzalutamide with an inhibitor of Stearoyl CoA Desaturase 1 (SCD1), an important enzyme in DNL, and observed significantly reduced tumor growth caused by the important change in tumoral lipid desaturation. Our findings suggest that the equilibrium between monounsaturated fatty acids and satu rated fatty acids is essential in the establishment of the more aggressive prostate cancer phenotype and that the combination therapy induces a disruption of this equilibrium leading to an important decrease of cell proliferation. These findings provide new insights into the role of DNL in the progression of prostate cancer cells. The study also provides the rationale for the use of an inhibitor of SCD1 in combination with enzalutamide to improve response, delay enzalutamide resistance and improve disease free progression. View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.